Methods for the Automated Manufacturing of an Autologous Dendritic-Cell Immunotherapy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Methods for the Automated Manufacturing of an Autologous Dendritic-Cell Immunotherapy
The authors developed automated equipment that uses functionally closed disposables to perform cellular and ribonucleic processing.


Pharmaceutical Technology
Volume 35, pp. s12-s17

Conclusion

These prototypes demonstrated the feasibility of this automated approach. The automated equipment and the associated disposable sets or components provides a platform technology to enable commercial manufacturing of complex autologous DC immunotherapies.

Tamara T. Monesmith is a director of manufacturing and process development at Argos Therapeutics, 4233 Technology Dr., Durham, NC 27704, tel. 919.287.6300, fax 919.287.6301,
.

References

1. J. Harris et al., Biochim. Biophys. Acta 1724 (1-2), 127–136 (2005).

2. I. Tcherepanova et al., PLoS One 1 (e1489), 1–10 (2008).

3. S.R. Bennett et al., Nature 393 (6684), 478–480 (1998).

4. J.P. Ridge, R.F. Di, and P. Matzinger, Nature 393 (6684), 474–478 (1998).

5. S.P. Schoenberger et al., Nature 393 (6684), 480–483 (1998).

6. P.T. Coates et al., Expert Rev. Mol. Med. 4 (3),1–21 (2002).

7. M.A. DeBenedette et al., J. Immunother. 34 (1), 45–57 (2011).

8. I.Y. Tcherepanova et al., BMC Mol. Biol. 9 (90), 1–13 (2008).

9. D.M. Calderhead et al., J. Immunother. 31 (8), 731-741 (2008).

10. M.A. DeBenedette et al., J. Immunol. 181 (8), 5296–5305 (2008).

11. A. Jemal et al., CA Cancer J. Clin. 60 (5), 277–300 (2010).

12. S.A. Karumanchi, J. Merchan, and V.P. Sukhatme, Curr. Opin. Nephrol. Hypertens. 11 (1), 37–42 (2002).

13. National Cancer Institute, SEER Cancer Statistics Review, 1975–2007, S.F. Altekruse et al., Eds. (NCI, Bethesda, MD, 2010).

14. K.J. Pienta and D.C. Smith, CA Cancer J. Clin. 55 (5), 300–318 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here